Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1

Interventions

Fluorouracil 13Cisplatin 7Radiotherapy 6Specimen Handling 5Mitomycin 5Capecitabine 5pembrolizumab 4dehydroftorafur 4Radiation 4Drug Therapy 4Cetuximab 4Radiotherapy, Intensity-Modulated 3Paclitaxel 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3Biopsy 3tislelizumab 2durvalumab 2aldesleukin 2VGX-3100 2Platinum 2Mitozytrex 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 21,2-diaminocyclohexaneplatinum II citrate 2toripalimab 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1spartalizumab 1rocakinogene sifuplasmid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anus Neoplasms × Adoptive Transfer × Clear all
NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡